Furthermore, the CITYSCAPE clinical trial (NCT03563716) evaluated the combination of the anti-TIGIT antibody tiragolumab in combination with the anti-PD-L1 antibody atezolizumab in patients with newly diagnosed non-small cell lung cancer whose tumours expressed PD-L1. This evidence concerns the gene CD274 and neoplasm.